Epizyme is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer through novel epigenetic medicines. The Company, headquartered in Cambridge, Massachusetts in the U.S., is focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take and based on a deep understanding of the patients that may benefit from them. The Company aspires to change the standard-of-care for patients and physicians by developing medicines with fundamentally new mechanisms of action. For more information, visit epizyme.com.

www.epizyme.com

Epizyme

Ipsen SAS is a global biopharmaceutical group focused on innovation and specialty care. The company provides transformative medicines to patients worldwide, with a strong emphasis on oncology and rare diseases. Ipsen is listed on Euronext Paris and is known for its commitment to research and development.

Ipsen Completes Acquisition Of Epizyme Expanding Its Portfolio In Oncology

Description

Company Information

Related People

M&A Insights

Ipsen Completes Acquisition Of Epizyme Expanding Its Portfolio In Oncology

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

M&A Insights

Company Information